# Marty Emerson

> Marty Emerson is the president and CEO of Monteris Medical, a Minnesota medical-device company behind the NeuroBlate MRI-guided laser ablation platform. An accounting graduate who moved through finance, sales and international management into the corner office, Emerson has led public and private device companies, guided Galil Medical through its acquisition by BTG, and steered Monteris through a major product recall toward wider adoption, clinical evidence and a new phase of expansion.

- **Role:** President and Chief Executive Officer at Monteris Medical
- **Organizations:** Monteris Medical, Nuwellis, SubioMed, Contraline, Galil Medical, American Medical Systems, Boston Scientific, Baxter International
- **Education:** Bachelor of Science in Accounting, Marquette University
- **Known for:** Led Galil Medical through its 2016 acquisition by BTG plc., Guided Monteris through a Class I product recall and the development of a redesigned laser probe cleared by the FDA in 2018., Oversaw Monteris as NeuroBlate expanded from more than 2,000 treated patients in 2018 to deployment in nearly 130 North American health systems by 2026.

## Career timeline

- **1985** — Joined Baxter International in a finance role after graduating from Marquette University.
- **1986** — Passed the CPA examination.
- **1990s** — Held management roles at Baxter International and Boston Scientific, including a general-manager assignment in Singapore late in the decade.
- **2000-2003** — Held international, global sales and marketing, and operating leadership roles at American Medical Systems.
- **2004-2005** — Served as president and chief operating officer of American Medical Systems.
- **2005-2008** — Served as president and CEO of publicly traded American Medical Systems.
- **2008-2016** — Served as president and CEO of Galil Medical and led the company through its acquisition by BTG plc.
- **2016-present** — Serves as president and CEO of Monteris Medical.
- **2019-present** — Serves as board chair of SubioMed.
- **2021-present** — Serves on the board of Contraline.
- **2026-present** — Serves as an independent director of Nuwellis and sits on its audit, compensation, and nominating and governance committees.

## Achievements

- Led Galil Medical through its 2016 acquisition by BTG plc.
- Guided Monteris through a Class I product recall and the development of a redesigned laser probe cleared by the FDA in 2018.
- Oversaw Monteris as NeuroBlate expanded from more than 2,000 treated patients in 2018 to deployment in nearly 130 North American health systems by 2026.
- Supported Monteris' long-running LAANTERN prospective registry, which enrolled more than 1,000 patients and produced multiple peer-reviewed publications.
- Led Monteris into a 2026 financing package comprising $28 million in Series E equity and a $35 million credit facility.
- Built more than 30 years of public- and private-company medical-device leadership and board experience.

## Latest updates

- **2026-08** — Monteris announced a Journal of Clinical Oncology publication analyzing 787 NeuroBlate-treated tumor patients across 25 U.S. centers, the ninth manuscript from its LAANTERN registry.
- **2026-03** — Monteris closed $28 million in Series E equity financing and established a $35 million credit facility to support technology development, clinical research, U.S. commercial expansion and geographic growth.
- **2026-02** — Nuwellis appointed Emerson to its board as an independent director; he joined the audit, compensation, and nominating and governance committees.
- **2026-01** — Monteris announced TRICARE coverage for laser interstitial thermal therapy following an advocacy effort with more than 30 military and veteran organizations.
- **2025-10** — Monteris and Symphony Robotics announced a collaboration on an AI-driven micro-robotic platform for laser ablation in the brain.

## Links

- Website: https://www.monteris.com/leadership/martin-emerson/
- LinkedIn: https://www.linkedin.com/in/marty-emerson-7957b86

---

Profile page: https://yespress.io/marty-emerson
Published by YesPress — https://yespress.io
Last updated: 2026-09-28